ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects (Cancer)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00955773
Recruitment Status : Completed
First Posted : August 10, 2009
Last Update Posted : November 9, 2017
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : November 8, 2011
  Actual Study Completion Date : November 8, 2011